HE4 Expression in Plasma Correlates with Surgical Outcome and Overall Survival in Patients with First Ovarian Cancer Relapse

被引:36
作者
Braicu, Elena Ioana [1 ]
Chekerov, Radoslav [1 ]
Richter, Rolf [1 ]
Pop, Carmen [1 ]
Nassir, Mani [1 ]
Loefgren, Hanna [1 ]
Stamatian, Florin [2 ]
Muallem, Mustafa Zelal [1 ]
Hall, Christina [3 ]
Fotopoulou, Christina [1 ]
Sehouli, Jalid [1 ]
Pietzner, Klaus [1 ]
机构
[1] Charite, Dept Gynecol, D-13353 Berlin, Germany
[2] Iuliu Hatieganu Med Univ, Dept Obstet & Gynecol, Cluj Napoca, Romania
[3] Fujirebio Diagnost, Gothenburg, Sweden
关键词
INDEPENDENT PROGNOSTIC-FACTOR; COMPLETE TUMOR RESECTION; PELVIC MASS; PROSPECTIVE VALIDATION; CYTOREDUCTIVE SURGERY; MALIGNANCY ALGORITHM; CONSECUTIVE PATIENTS; CA-125; LEVELS; CA125; CARCINOMA;
D O I
10.1245/s10434-013-3347-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Epithelial ovarian cancer (EOC) remains the main cause of mortality due to gynecological malignancies. Optimal tumor debulking and platinum response are the most important prognostic factors for overall survival (OS) in primary EOC. In the setting of recurrence, the role of cytoreduction is not clear. A critical point is to predict preoperatively the subgroup of patients with optimal surgical outcome. The aim of the study was to analyze the predictive role of HE4 for surgical outcome and platinum response in EOC patients experiencing a first relapse. Secondary aims were the prognostic role of HE4 for OS and progression-free survival (PFS). Methods. Plasma was obtained before secondary cytoreduction from 73 EOC patients. A total of 66.7 % underwent a total macroscopic tumor clearance; 86.3 % of the patients had disease that responded to platinum therapy. HE4 was detected by enzyme-linked immunosorbent assay. For statistical analysis, the chi-square test, Fisher's exact test, Kendall's tau b, and Mann-Whitney U test were used. OS, PFS rates, and respective 95 % confidence intervals (CI) were estimated according to the Kaplan-Meier method. Results. At a HE4 cutoff value of 250 pMk, a sensitivity of 52 % and a specificity of 93.8 % (p = 0.001, 95 % CI 0.601-0.861) were reached in predicting total macroscopic tumor clearance. Plasma HE4 concentrations together with platinum response were the only independent prognostic factors for OS (p < 0.001, hazard ratio [HR] 18.77, 95 % CI 4.68-75.25; and p = 0.044, HR 3.33, 95 % CI 1.03-10.7, respectively). Together with ascites, HE4 was the only independent predictive factor for surgical outcome (p = 0.029, odds ratio [OR] 7.2, 95 % CI 1.22-42.19 and p = 0.036, OR 10.18, 95 % CI 1.16-88.69, respectively). Conclusions. HE4 is an independent predictive marker for surgical outcome and OS in patients with recurrent EOC. Larger population studies are needed to validate these results.
引用
收藏
页码:955 / 962
页数:8
相关论文
共 31 条
[1]   Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? [J].
Angioli, Roberto ;
Plotti, Francesco ;
Capriglione, Stella ;
Aloisi, Alessia ;
Montera, Roberto ;
Luvero, Daniela ;
Miranda, Andrea ;
Cafa, Ester Valentina ;
Damiani, Patrizio ;
Benedetti-Panici, Pierluigi .
GYNECOLOGIC ONCOLOGY, 2013, 128 (03) :579-583
[2]   The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer [J].
Barlow, TS ;
Przybylski, M ;
Schilder, JM ;
Moore, DH ;
Look, KY .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (02) :496-500
[3]   Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients Results from the OVCAD study [J].
Braicu, E. I. ;
Fotopoulou, C. ;
Van Gorp, T. ;
Richter, R. ;
Chekerov, R. ;
Hall, C. ;
Butz, H. ;
Castillo-Tong, D. Cacsire ;
Mahner, S. ;
Zeillinger, R. ;
Concin, N. ;
Vergote, I. ;
Sehouli, J. .
GYNECOLOGIC ONCOLOGY, 2013, 128 (02) :245-251
[4]   Primary versus secondary cytoreduction for epithelial ovarian cancer: A paired analysis of tumour pattern and surgical outcome [J].
Braicu, Elena-Ioana ;
Sehouli, Jalid ;
Richter, Rolf ;
Pietzner, Klaus ;
Lichtenegger, Werner ;
Fotopoulou, Christina .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (05) :687-694
[5]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[6]   Advanced ovarian cancer. [J].
Chi D.S. ;
Sabbatini P. .
Current Treatment Options in Oncology, 2000, 1 (2) :139-146
[7]   Preoperative CA 125 levels: An independent prognostic factor for epithelial ovarian cancer [J].
Cooper, BC ;
Sood, AK ;
Davis, CS ;
Ritchie, JM ;
Sorosky, JI ;
Anderson, B ;
Buller, RE .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (01) :59-64
[8]   Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study [J].
Eisenkop, SM ;
Spirtos, NM ;
Friedman, RL ;
Lin, WCM ;
Pisani, AL ;
Perticucci, S .
GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :390-396
[9]   Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients [J].
Fotopoulou, C. ;
Richter, R. ;
Braicu, E. I. ;
Schmidt, S. -C. ;
Lichtenegger, W. ;
Sehouli, J. .
EJSO, 2010, 36 (12) :1202-1210
[10]   Clinical Outcome of Tertiary Surgical Cytoreduction in Patients with Recurrent Epithelial Ovarian Cancer [J].
Fotopoulou, Christina ;
Richter, Rolf ;
Braicu, Ioana Elena ;
Schmidt, Sven-Christian ;
Neuhaus, Peter ;
Lichtenegger, Werner ;
Sehouli, Jalid .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (01) :49-57